Please login to the form below

Not currently logged in
Email:
Password:

Strimvelis

This page shows the latest Strimvelis news and features for those working in and with pharma, biotech and healthcare.

J&J bolsters gene therapy unit with $100m MeiraGTx deal

J&J bolsters gene therapy unit with $100m MeiraGTx deal

GlaxoSmithKline launched its Strimvelis product in 2016, but sold it to Orchard Therapeutics last year after opting to exit the rare disease category.

Latest news

More from news
Approximately 4 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    pancreatitis. Then GSK’s Strimvelis followed in 2016 for a very rare disease called ADA-SCID (Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency). ... GSK has also had very limited success with Strimvelis and has now sold on the

  • Health on instalment Health on instalment

    Another EU drug, Strimvelis, targeting immune deficiency, retails for $665, 000.

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Two Advanced Therapy Medicinal Products (ATMP), Strimvelis (for the treatment of severe combined immunodeficiency) and Zalmoxis (for the treatment of certain types of high-risk haematological malignancies), were approved in the

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Weekly industry appointments Weekly industry appointments

    There, he is medicines development leader for adenosine deaminase deficiency (ADA-SCID) gene therapy Strimvelis – the first alternative medicine to stem cell transplant for the disease that’s bagged a regulatory

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Solaris Health looks at the gene therapy revolution

    As an example, in the case of Strimvelis (autologous CD34. cells transduced to express adenosine deaminase [ADA]), the first ex vivo stem cell gene therapy approved by the EMA (European Medicines ... https://www.ncbi.nlm.nih.gov/books/NBK1483/ (accessed

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics